Compare Analog Devices, Inc. (ADI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Sanofi SA — how do they compare? Analog Devices, Inc. trades at $417.07 (market cap $202.12B), while Sanofi SA trades at $44.34 (market cap $106.83B). The key difference: Analog Devices, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.45%). Which is the better fit depends on your goals — on Pluang, investors hold Analog Devices, Inc. for 64 Days and Sanofi SA for 95 Days on average.
| ADI | SNY | |
|---|---|---|
Market Cap | $202.12B | $106.83B |
Volume | 7,876,360 | 15,100,460 |
Sector | Technology | Health |
52-Week High | $445.48 | $52.34 |
52-Week Low | $225.20 | $39.12 |
Typical Hold Time | 64 Days | 95 Days |
Enterprise Value | $208.91B | $122.35B |
Dividend Yield | 1.05% | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $417.07, down 3.74% on the day, but maintains strong analyst support with 83% buy ratings and a $480.24 consensus price target. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.45 exceeding expectations. Technical indicators show a bullish moving average trend while fundamentals reveal robust profitability with 29.79% net income margin and double-digit growth projections into 2027 driven by data center and industrial demand.
ADI presents a compelling investment case with strong earnings momentum and institutional confidence, though elevated valuation ratios (P/E 49.54) and RSI near overbought levels warrant caution. The stock offers upside to analyst targets but faces competition and inventory normalization risks in the semiconductor sector. Bank of America's recent $3.57 billion investment underscores institutional belief in ADI's growth trajectory.
Sanofi (SNY) trades at $44.34, up 2.81% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Recent expansion of the immunology alliance with Regeneron, valued up to $8 billion, highlights strategic growth initiatives beyond the blockbuster Dupixent franchise.
The outlook remains positive with revenue growth and margin expansion, though investors face risks from patent expirations and competitive pressures. Analyst consensus leans neutral with 44% buy ratings, while institutional sentiment is balanced between technical strength and valuation considerations amid ongoing pipeline development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
